A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability, Pharmacokinetics, and Pharmacodynamics of APD791 Administered to Healthy Adult Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability, Pharmacokinetics, and Pharmacodynamics of APD791 Administered to Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2008

At a glance

  • Drugs Temanogrel (Primary)
  • Indications Arterial thrombosis; Thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 09 Jan 2008 Status changed from recruiting to completed, in accordance with media release 9084166.
    • 09 Jan 2008 Results reported by Arena Pharmaceuticals.
    • 18 Jul 2007 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top